Physician profile
Darryl A Hill
NPI 1013978790
$2,258.58
in general payments reported to CMS, 2019-2025
20 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $210 · 2021: $567 · 2022: $343 · 2023: $129 · 2024: $655 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $759.31 | 2020-2023 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $629.68 | 2021-2025 | Airsupra, Tezspire, Farxiga |
| Medtronic, INC. | $160.54 | 2024 | Minimed 780g |
| Exact Sciences Corporation | $114.51 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $110.44 | 2024-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $89.84 | 2020-2024 | |
| Vertex Pharmaceuticals Incorporated | $45.00 | 2024 | |
| Abbott Laboratories | $44.92 | 2019-2024 | Freestyle Libre 3 |
| Arbor Pharmaceuticals, INC. | $43.52 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.97 | 2019 | |
| Azurity Pharmaceuticals, INC. | $33.98 | 2023 | Edarbi |
| Biohaven Pharmaceuticals, INC. | $26.25 | 2021 | |
| Intra-Sana Laboratories | $26.25 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Lexicon Pharmaceuticals, INC. | $26.08 | 2024 | |
| Dexcom, INC. | $23.12 | 2025 | Dexcom G6 Transmitter |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $23.04 | 2024 | |
| Indivior INC. | $21.77 | 2019 | |
| Xeris Pharmaceuticals, INC. | $16.78 | 2025 | Gvoke Hypopen |
| Tactile Systems Technology INC | $13.15 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darryl Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.